

Curriculum Vitae and Bibliography

Grzegorz S Nowakowski, MD

Personal Information

Work Address: Mayo Clinic
200 First Street SW
Rochester, MN 55905
507-284-2511

Email Address: Nowakowski.Grzegorz@mayo.edu

Present Academic Rank and Position

Assistant Professor of Medicine - Mayo Clinic College of Medicine 07/2006 - Present

Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 06/2011 - Present

Education Chair - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 07/2012 - Present

Advanced Hematology Fellowship Program Director - Hematology/Oncology Fellowship Program, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, Rochester, Minnesota 07/2015 - Present

Education

Medical University of Warsaw - MD 1992 - 1998

Mississauga Hospital, Ontario, Canada - Clerkship, Summer, Medical Oncology/Internal Medicine 1996

Mississauga Hospital, Ontario, Canada - Clerkship, Summer, Medical Oncology/Internal Medicine 1997

University of Massachusetts Cancer Center, Worcester, MA - Research Fellowship, Experimental Bone Marrow Transplantation 1998 - 1999

Yale University Medical School-Norwalk Hospital - Resident, Internal Medicine 1999 - 2002

Hematology/Oncology Fellowship Program, Programs in Rochester, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine - Fellow 2002 - 2006

Additional Education

Clinical Research Training Institute
Competitive Workshop, American Society of Hematology 2004

Molecular Biology in Cancer Research
Competitive Workshop, American Association for Cancer Research, American Society of Clinical Oncology 2004

Certification

Board Certifications

American Board of Internal Medicine (ABIM)

Medical Oncology 2005 - Present

Hematology 2006 - Present

Educational Commission for Foreign Medical Graduates (ECFMG)

ECFMG	1998 - Present
-------	----------------

Licensure

Minnesota	45077 (Medical)	01/2002 - Present
-----------	-----------------	-------------------

Honors and Awards

Scholarships for High Academic Achievements - Medical University of Warsaw	01/1992 - 01/1998
High Distinction Graduate Award - Medical University of Warsaw and Ministry of Health, Poland	01/1998
Worldwide Institute for Support of Culture & Student Exchange Scholarship - Awarding Organization	01/1998
ASH Merit Award - Best Abstract in Resident Physician Category - American Society of Hematology	01/2000
Best Clinical Vignette - American College of Physicians-American Society of Internal Medicine	01/2001
Outstanding Graduate Award - Norwalk Hospital, Yale University School of Medicine	01/2002
President's Award for Scientific Excellence - International Society for Preventive Oncology	01/2002
Robert A. Kyle Research Award - Mayo Clinic College of Medicine	01/2003
Merit Award - American Society of Clinical Oncology	01/2005
William H. J. Summerskill Award - Mayo Clinic	01/2006
Best Educators for Resident Education - Department of Internal Medicine, Mayo Clinic	09/2011
Leadership Development Program - American Society of Clinical Oncology	05/2012
2012 Teacher of the Year - Hematology-Oncology Fellows	06/2012

Previous Professional Positions and Major Appointments

Instructor of Medicine - Mayo Clinic College of Medicine	04/2003 - 06/2006
Mayo Foundation Scholar - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	07/2006 - 06/2008
Senior Associate Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	07/2008 - 06/2011
Program Director - Hematology/Oncology Fellowship Program, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, Rochester, Minnesota	07/2013 - 06/2015

Professional and Community Memberships, Societies, and Services**Professional Memberships and Services**

American Society of Clinical Oncology

Member

American Society of Hematology

Annual Meeting

European Hematology Association

Member

International Extranodal Lymphoma Study Group

Member

Journal Responsibilities

Journal Other Responsibilities

American Journal of Hematology

Reviewer

Blood

Reviewer

British Journal of Haematology

Reviewer

Cancer

Reviewer

Genes, Chromosomes and Cancer

Reviewer

Journal of Clinical Oncology

Abstract Reviewer

Reviewer

Lancet Oncology

Reviewer

Leukemia

Reviewer

Leukemia and Lymphoma

Reviewer

Leukemia Research

Reviewer

Molecular Cancer Research

Reviewer

Educational Activities

Curriculum and Course Development

Advanced Fellowship in Hematology

MSGME

Rochester, Minnesota

07/2015 - Present

Institutional/Departmental Administrative Responsibilities, Committee Memberships, and Other Activities

Mayo Clinic

Department of Education Administration Mayo Clinic College of Medicine Mayo School of Graduate Medical Education Mayo Fellows Association Member	
Mayo Clinic Center for Individualized Medicine Consultant	01/2013 - Present
Mayo Clinic in Rochester	
Department of Internal Medicine Division of Hematology Chronic Lymphocytic Leukemia Study Group Member	
Education Committee Chair	07/2013 - Present
Executive Committee Member	11/2011
Large Granular Leukemia Study Chair	
Lymphoma Study Group Member	
Faculty Development Committee Member	07/2012 - 07/2015
Graduate Education Committee Member	07/2013 - 06/2015
Hematology/Oncology Educational Committee Chair	07/2013 - Present
Activities at Other Institutions	
American Society of Clinical Oncology Education Committee Member	05/2013 - 05/2016
American Society of Hematology Lymphoma Biology Meeting Steering Committee Member	09/2013 - Present
Maintenance of Certification Committee Chair	07/2013 - Present
Scientific Affairs Committee Chair	04/2011 - 04/2014
Member	12/2012 - 12/2015
Scientific Committee on Immunity and Host Defence Member	12/2008 - 12/2011
Test Material Development Committee Member	04/2008 - 04/2011
Training Program Committee Ex-Officio	
Eastern Cooperative Oncology Group Lymphoma Core Committee Member	11/2011 - Present
International Extranodal Lymphoma Study Group	

Member

07/2008 - Present

Clinical Practice, Interests, and Accomplishments

Therapy of lymphoproliferative disorders, particularly targeted agents and novel, precision medicine approaches.

Research Interests

My long-term goal is to improve the outcomes of patients with lymphoproliferative disorders through the development of novel therapies. My research focuses on i) the biology of B-cell malignancies, particularly identification of new therapeutic targets and biomarkers for the selection of therapy ii) the development of clinical trials based on tumor biology and/or novel therapeutic targets. I am a member of Mayo Clinic Cancer Center Lymphoma Disease Oriented Group, and I am actively involved and work with Mayo Clinic Lymphoma database and Lymphoma Tissue bank. The focus of my laboratory has been on pre-clinical testing of new agents in lymphoma therapy with the goal of rapid translation to the clinic. In this regard, we are fortunate to have an access to primary human lymphoma cells through Mayo Clinic Lymphoma Tissue Bank for preclinical testing. I am a PI or a co-PI of multiple clinical trials in lymphoma, including early phase 1 and phase 2 trials. I am also a PI of collaborative group NCI sponsored clinical trials within the Eastern Cooperative Oncology Group (E1412) and the ALIANCE (N0188). My role in Lymphoma Disease Oriented Group and as PI of multiple clinical trials, enables me with ability to translate laboratory discoveries to biomarker driven therapies of patients with lymphoma.

Educational Practice, Interests, and Accomplishments

Advanced hematology-oncology graduate education. Standardized testing and MOC.

Bibliography

Peer-reviewed Articles

1. Berrios VM, Dooner GJ, **Nowakowski G**, Frimberger A, Valinski H, Quesenberry PJ, Becker PS. The molecular basis for the cytokine-induced defect in homing and engraftment of hematopoietic stem cells. *Exp Hematol*. 2001 Nov; 29(11):1326-35. PMID:11698129
2. **Nowakowski GS**, Katz A. Epilepsia partialis continua as an atypical presentation of cat scratch disease in a young adult. *Neurology*. 2002 Dec 10; 59(11):1815-6. PMID:12473786
3. **Nowakowski GS**, Dooner MS, Valinski HM, Mihaliak AM, Quesenberry PJ, Becker PS. A specific heptapeptide from a phage display peptide library homes to bone marrow and binds to primitive hematopoietic stem cells. *Stem Cells*. 2004; 22(6):1030-8. PMID:15536193 DOI:10.1634/stemcells.22-6-1030
4. **Nowakowski GS**, Call TG, Morice WG, Kurtin PJ, Cook RJ, Zent CS. Clinical significance of monoclonal B cells in cerebrospinal fluid. *Cytometry B Clin Cytom*. 2005 Jan; 63(1):23-7. PMID:15624205 DOI:10.1002/cyto.b.20032
5. **Nowakowski GS**, Morice WG, Phyliky RL, Li CY, Tefferi A. Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia. *Br J Haematol*. 2005 Feb; 128(4):490-2. PMID:15686456 DOI:10.1111/j.1365-2141.2004.05341.x
6. **Nowakowski GS**, Dewald GW, Hoyer JD, Paternoster SF, Stockero KJ, Fink SR, Smoley SA, Remstein ED, Phyliky RL, Call TG, Shanafelt TD, Kay NE, Zent CS. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. *Br J Haematol*. 2005 Jul; 130(1):36-42. PMID:15982342 DOI:10.1111/j.1365-2141.2005.05548.x
7. **Nowakowski GS**, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, Lust JA, Dispenzieri A, Greipp PR, Kyle RA, Rajkumar SV. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. *Blood*. 2005 Oct 1; 106(7):2276-9. Epub 2005 Jun 16. PMID:15961515 PMID:1895270 DOI:10.1182/blood-2005-05-1858
8. Dingli D, Rajkumar SV, **Nowakowski GS**, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. *Haematologica*. 2005 Dec; 90(12):1650-4. PMID:16330438
9. **Nowakowski GS**, Rajkumar SV. New treatments for multiple myeloma. *Oncology*. 2005 Dec; 19(14):1752-3.
10. Dingli D, **Nowakowski GS**, Dispenzieri A, Lacy MQ, Hayman S, Litzow MR, Gastineau DA, Gertz MA. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. *Clin Lymphoma Myeloma*. 2006 Mar; 6(5):384-8. PMID:16640814 DOI:10.3816/CLM.2006.n.014
11. **Nowakowski GS**, Witzig TE. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. *Clin Adv Hematol Oncol*. 2006 Mar; 4(3):225-31. PMID:16728934
12. Liang KV, Sanderson SO, **Nowakowski GS**, Arora AS. Metastatic malignant melanoma of the gastrointestinal tract. *Mayo Clin Proc*. 2006 Apr; 81(4):511-6. PMID:16610571 DOI:10.4065/81.4.511
13. Dingli D, **Nowakowski GS**, Dispenzieri A, Lacy MQ, Hayman SR, Rajkumar SV, Greipp PR, Litzow MR, Gastineau DA, Witzig TE, Gertz MA. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. *Blood*. 2006 Apr 15; 107(8):3384-8. Epub 2005 Dec 08. PMID:16339399 PMID:1895764 DOI:10.1182/blood-2005-08-3398
14. Shanafelt TD, Lee YK, Call TG, **Nowakowski GS**, Dingli D, Zent CS, Kay NE. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. *Leuk Res*. 2006 Jun; 30(6):707-12. Epub 2005 Dec

01. PMID:16325256 DOI:10.1016/j.leukres.2005.10.020
15. Dingli D, Kyle RA, Rajkumar SV, **Nowakowski GS**, Larson DR, Bida JP, Gertz MA, Therneau TM, Melton LJ 3rd, Dispenzieri A, Katzmann JA. Immunoglobulin free light chains and solitary plasmacytoma of bone. *Blood*. 2006 Sep 15; 108(6):1979-83. Epub 2006 Jun 01. PMID:16741249 PMCID:1895544 DOI:10.1182/blood-2006-04-015784
16. **Nowakowski GS**, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. *Clin Cancer Res*. 2006 Oct 15; 12(20 Pt 1):6087-93. PMID:17062684 DOI:10.1158/1078-0432.CCR-06-1015
17. **Nowakowski GS**, Hoyer JD, Shanafelt TD, Geyer SM, LaPlant BR, Call TG, Jelinek DF, Zent CS, Kay NE. Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. *Mayo Clin Proc*. 2007 Apr; 82(4):449-53. PMID:17418074 DOI:10.4065/82.4.449
18. Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS, **Nowakowski GS**, Call TG, Dewald GW, Jelinek DF. Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. *J Clin Invest*. 2008 Jan; 118(1):306-15. PMID:18064298 PMCID:2117767 DOI:10.1172/JCI32625
19. Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, **Nowakowski GS**, Zent CS, Call TG, Laplant B, Dewald GW, Jelinek DF, Kay NE. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. *Br J Haematol*. 2008 Mar; 140(5):537-46. PMID:18275431 PMCID:4477272 DOI:10.1111/j.1365-2141.2007.06965.x
20. Wu X, Darce JR, Chang SK, **Nowakowski GS**, Jelinek DF. Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells. *Blood*. 2008 Dec 1; 112(12):4675-82. Epub 2008 Aug 06. PMID:18684869 PMCID:2597133 DOI:10.1182/blood-2008-03-145995
21. **Nowakowski GS**, Hoyer JD, Shanafelt TD, Zent CS, Call TG, Bone ND, Laplant B, Dewald GW, Tschumper RC, Jelinek DF, Witzig TE, Kay NE. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. *J Clin Oncol*. 2009 Apr 10; 27(11):1844-9. Epub 2009 Mar 02. PMID:19255329 PMCID:2668708 DOI:10.1200/JCO.2008.17.0795
22. **Nowakowski GS**, Shanafelt TD, Schwager S, Kay NE. Reply to R.S. Go. *J Clin Oncol*. 2009 Jul 06. [Epub ahead of print] PMID:19581529 DOI:10.1200/JCO.2009.23.8683
23. Ding W, **Nowakowski GS**, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK, Secreto CR, Medina KL, Shanafelt TD, Zent CS, Call TG, Kay NE. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. *Br J Haematol*. 2009 Nov; 147(4):471-83. Epub 2009 Sep 08. PMID:19751240 PMCID:2783570 DOI:10.1111/j.1365-2141.2009.07868.x
24. Wu X, Tschumper RC, Gutierrez A Jr, Mihalcik SA, **Nowakowski GS**, Jelinek DF. Selective induction of DNA repair pathways in human B cells activated by CD4+ T cells. *PLoS One*. 2010; 5(12):e15549. Epub 2010 Dec 16. PMID:21179576 PMCID:3002972 DOI:10.1371/journal.pone.0015549
25. **Nowakowski GS**, Maurer MJ, Habermann TM, Ansell SM, Macon WR, Ristow KM, Allmer C, Slager SL, Witzig TE, Cerhan JR. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. *J Clin Oncol*. 2010 Jan 20; 28(3):412-7. Epub 2009 Dec 14. PMID:20008638 PMCID:2815703 DOI:10.1200/JCO.2009.23.4245
26. Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Colgan JP, **Nowakowski GS**, Thompson CA, Markovic SN. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. *Leukemia*. 2010 Jul; 24(7):1343-9. Epub 2010 May 20. PMID:20485372 DOI:10.1038/leu.2010.108
27. Shanafelt TD, Rabe KG, Kay NE, Zent CS, Call TG, Slager SL, Bowen DA, Schwager SM, **Nowakowski GS**.

Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. *Leuk Lymphoma*. 2010 Jul; 51(7):1233-40. PMID:20496995 PMID:3913168 DOI:10.3109/10428194.2010.486877

28. **Nowakowski GS**, Maurer MJ, Witzig TE, Cerhan JR. Reply to C. Barker et Al and h. Asai et Al. *J Clin Oncol*. 2010 Aug 20; 28(24):e427-8. Epub 2010 Jun 21 PMID:20567004 DOI:10.1200/JCO.2010.28.9710
29. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, **Nowakowski GS**, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. *Mayo Clin Proc*. 2010 Sep; 85(9):824-33. Epub 2010 Aug 11. PMID:20702770 PMID:2931618 DOI:10.4065/mcp.2010.0304
30. Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN, Kelly JL, Macon WR, **Nowakowski GS**, Inwards DJ, Johnston PB, Singh RJ, Allmer C, Slager SL, Weiner GJ, Witzig TE, Cerhan JR. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. *J Clin Oncol*. 2010 Sep 20; 28(27):4191-8. Epub 2010 Aug 16. PMID:20713849 PMID:2953973 DOI:10.1200/JCO.2010.28.6674
31. Maurer MJ, Micallef IN, Cerhan JR, Katzmann JA, Link BK, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Porrata LF, Johnston PB, **Nowakowski GS**, Thompson CA, Gupta M, Syrbu SI, Kurtin PJ, Macon WR, Nikcevich DA, Witzig TE. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. *J Clin Oncol*. 2011 Apr 20; 29(12):1620-6. Epub 2011 Mar 07. PMID:21383282 PMID:3082979 DOI:10.1200/JCO.2010.29.4413
32. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, **Nowakowski GS**, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. *Leukemia*. 2011 Sep; 25(9):1502-9. Epub 2011 May 24. PMID:21606957 DOI:10.1038/leu.2011.112
33. Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE, **Nowakowski GS**. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. *Br J Haematol*. 2011 Oct; 155(1):53-64. Epub 2011 Jul 12. PMID:21749361 PMID:4405035 DOI:10.1111/j.1365-2141.2011.08794.x
34. Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, **Nowakowski GS**, Thompson CA, Allmer C, Maurer MJ, Gupta M, Weiner G, Hohl R, Kurtin PJ, Ding H, Loegering D, Schneider P, Peterson K, Habermann TM, Kaufmann SH. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. *Blood*. 2011 Nov 3; 118(18):4882-9. Epub 2011 Jul 01. PMID:21725056 PMID:3208296 DOI:10.1182/blood-2011-02-334904
35. **Nowakowski GS**, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. *Leukemia*. 2011 Dec; 25(12):1877-81. Epub 2011 Jul 01. PMID:21720383 DOI:10.1038/leu.2011.165
36. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, **Nowakowski GS**, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. *Haematologica*. 2012 Feb; 97(2):262-9. Epub 2011 Oct 11. PMID:21993683 PMID:3269488 DOI:10.3324/haematol.2011.050138
37. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, **Nowakowski GS**, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. *Leuk Lymphoma*. 2012 Apr; 53(4):575-80. Epub 2012 Jan 03. PMID:22098403 DOI:10.3109/10428194.2011.637211

38. Ansell SM, Tang H, Kurtin PJ, Koenig PA, **Nowakowski GS**, Nikcevich DA, Nelson GD, Yang Z, Grote DM, Ziesmer SC, Silberstein PT, Erlichman C, Witzig TE. Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma. *Leukemia* 2012 May; 26 (5):1046-52 Epub 2011 Oct 21 PMID:22015775 PMCID:3266999 DOI:10.1038/leu.2011.297
39. Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, **Nowakowski GS**, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. *Br J Haematol.* 2012 May; 157(3):321-30. Epub 2012 Feb 24. PMID:22360654 DOI:10.1111/j.1365-2141.2012.09067.x
40. Kelly JL, Drake MT, Fredericksen ZS, Asmann YW, Liebow M, Shanafelt TD, Feldman AL, Ansell SM, Macon WR, Herr MM, Wang AH, **Nowakowski GS**, Call TG, Habermann TM, Slager SL, Witzig TE, Cerhan JR. Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma. *Cancer Causes Control.* 2012 Jul; 23(7):1017-29. Epub 2012 Apr 28. PMID:22544453 PMCID:3589750 DOI:10.1007/s10552-012-9967-0
41. Porrata LF, Ristow K, Habermann TM, Ozsan N, Dogan A, Macon W, Colgan JP, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, **Nowakowski GS**, Thompson C, Markovic SN. Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. *Leuk Lymphoma.* 2012 Nov; 53(11):2159-65. Epub 2012 May 21. PMID:22551474 DOI:10.3109/10428194.2012.690605
42. Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, **Nowakowski GS**, Zent CS. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. *Leuk Lymphoma.* 2012 Nov; 53(11):2218-27. Epub 2012 May 21. PMID:22475085 DOI:10.3109/10428194.2012.681657
43. Porrata LF, Ristow KM, Habermann TM, Macon WR, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, **Nowakowski G**, Thompson CA, Markovic SN. Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma. *Blood Cancer J.* 2013; 3:e110. Epub 2013 Apr 19. PMID:23599022 PMCID:3641323 DOI:10.1038/bcj.2013.8
44. Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, **Nowakowski GS**, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. *Am J Hematol.* 2013 Jul; 88(7):589-93. Epub 2013 Jun 12. PMID:23619698 PMCID:3951424 DOI:10.1002/ajh.23460
45. West DS, Dogan A, Quint PS, Tricker-Klar ML, Porcher JC, Ketterling RP, Law ME, McPhail ED, Viswanatha DS, Kurtin PJ, Dao LN, Ritzer RD, **Nowakowski GS**, Feldman AL. Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation. *Am J Surg Pathol.* 2013 Jul; 37(7):978-86. PMID:23759932 DOI:10.1097/PAS.0b013e318283099f
46. Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, Colgan JP, Inwards DJ, Ansell SM, Porrata LF, Micallef IN, Johnston PB, Markovic SN, Thompson CA, **Nowakowski GS**, Witzig TE. Bowel perforation in intestinal lymphoma: incidence and clinical features. *Ann Oncol.* 2013 Sep; 24(9):2439-43. Epub 2013 May 22. PMID:23704194 PMCID:3755328 DOI:10.1093/annonc/mdt188
47. Link BK, Maurer MJ, **Nowakowski GS**, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. *J Clin Oncol.* 2013 Sep 10; 31(26):3272-8. Epub 2013 Jul 29. PMID:23897955 PMCID:3757293 DOI:10.1200/JCO.2012.48.3990
48. Briski R, Feldman AL, Bailey NG, Lim MS, Ristow K, Habermann TM, Macon WR, Inwards DJ, Colgan JP, **Nowakowski GS**, Kaminski MS, Witzig TE, Ansell SM, Wilcox RA. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. *Blood Cancer J.* 2014; 4:e214. Epub 2014

May 30. PMID:24879115 PMCID:4042304 DOI:10.1038/bcj.2014.34

49. Baig NA, Taylor RP, Lindorfer MA, Church AK, LaPlant BR, Pettinger AM, Shanafelt TD, **Nowakowski GS**, Zent CS. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. *J Immunol*. 2014 Feb 15; 192(4):1620-9. Epub 2014 Jan 15. PMID:24431228 PMCID:4391060 DOI:10.4049/jimmunol.1302954
50. Smeltzer JP, Jones JM, Ziesmer SC, Grote DM, Xiu B, Ristow KM, Yang ZZ, **Nowakowski GS**, Feldman AL, Cerhan JR, Novak AJ, Ansell SM. Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. *Clin Cancer Res*. 2014 Jun 1; 20(11):2862-72. Epub 2014 Apr 11. PMID:24727328 PMCID:4058762 DOI:10.1158/1078-0432.CCR-13-2367
51. Jackson AE, Smeltzer JP, Habermann TM, Jones JM, Burnette B, Ristow K, Wiseman GA, Macon WR, **Nowakowski GS**, Witzig TE. The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement. *Am J Hematol*. 2014 Sep; 89(9):865-7. Epub 2014 Jun 19. PMID:24823914 DOI:10.1002/ajh.23760
52. Paludo J, Kapoor P, Oliveira JL, Garrity JA, **Nowakowski GS**. Mantle cell lymphoma: a great masquerader. *Int J Hematol*. 2014 Oct; 100(4):313-4. Epub 2014 Jul 30. PMID:25073863 DOI:10.1007/s12185-014-1642-7
53. Skibola CF, Berndt SI, Vijai J, Conde L, Wang Z, Yeager M, de Bakker PI, Birmann BM, Vajdic CM, Foo JN, Bracci PM, Vermeulen RC, Slager SL, de Sanjose S, Wang SS, Linet MS, Salles G, Lan Q, Severi G, Hjalgrim H, Lightfoot T, Melbye M, Gu J, Ghesquieres H, Link BK, Morton LM, Holly EA, Smith A, Tinker LF, Teras LR, Krickler A, Becker N, Purdue MP, Spinelli JJ, Zhang Y, Giles GG, Vineis P, Monnereau A, Bertrand KA, Albanes D, Zeleniuch-Jacquotte A, Gabbas A, Chung CC, Burdett L, Hutchinson A, Lawrence C, Montalvan R, Liang L, Huang J, Ma B, Liu J, Adami HO, Glimelius B, Ye Y, **Nowakowski GS**, Dogan A, Thompson CA, Habermann TM, Novak AJ, Liebow M, Witzig TE, Weiner GJ, Schenk M, Hartge P, De Roos AJ, Cozen W, Zhi D, Akers NK, Riby J, Smith MT, Lacher M, Villano DJ, Maria A, Roman E, Kane E, Jackson RD, North KE, Diver WR, Turner J, Armstrong BK, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, McKay J, Brooks-Wilson AR, Zheng T, Holford TR, Chamosa S, Kaaks R, Kelly RS, Ohlsson B, Travis RC, Weiderpass E, Clavel J, Giovannucci E, Kraft P, Virtamo J, Mazza P, Cocco P, Ennas MG, Chiu BC, Fraumeni JF Jr, Nieters A, Offit K, Wu X, Cerhan JR, Smedby KE, Chanock SJ, Rothman N. Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. *Am J Hum Genet* 2014 Oct 2; 95 (4):462-71 PMID:25279986 PMCID:4185120 DOI:10.1016/j.ajhg.2014.09.004
54. Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, Chassagne-Clement C, Inwards DJ, Gargi T, Johnston PB, Nicolas-Virelizier E, Macon WR, Peix M, Micallef IN, Sebban C, **Nowakowski GS**, Porrata LF, Weiner GJ, Witzig TE, Habermann TM, Link BK. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. *J Clin Oncol*. 2014 Nov 1; 32(31):3506-12. Epub 2014 Sep 29. PMID:25267745 PMCID:4209102 DOI:10.1200/JCO.2014.55.7561
55. Witzig TE, Maurer MJ, Habermann TM, Link BK, Micallef IN, **Nowakowski GS**, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Markovic SN, Johnston PB, Lin Y, Thompson C, Gupta M, Katzmann JA, Cerhan JR. Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma. *Am J Hematol*. 2014 Dec; 89(12):1116-20. Epub 2014 Sep 26. PMID:25228125 PMCID:4362722 DOI:10.1002/ajh.23839
56. Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, **Nowakowski G**, Thompson CA, Markovic SN. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2014 Dec; 55(12):2728-38. Epub 2014 Mar 19. PMID:24547705 DOI:10.3109/10428194.2014.893313
57. **Nowakowski GS**, Ansell SM. Therapeutic targeting of microenvironment in follicular lymphoma. *Hematology Am Soc Hematol Educ Program*. 2014 Dec 5; 2014(1):169-73. Epub 2014 Nov 18. PMID:25696851 DOI:10.1182/asheducation-2014.1.169
58. **Nowakowski GS** , Czuczman MS . ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does

Subtype Make a Difference in Therapy Selection? Am Soc Clin Oncol Educ Book 2015; e449-57 PMID:25993209
DOI:10.14694/EdBook_AM.2015.35.e449

59. Novak AJ , Asmann YW , Maurer MJ , Wang C , Slager SL , Hodge LS , Manske M , Price-Troska T , Yang ZZ , Zimmermann MT , **Nowakowski GS** , Ansell SM , Witzig TE , McPhail E , Ketterling R , Feldman AL , Dogan A , Link BK , Habermann TM , Cerhan JR . Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. Blood Cancer J 2015; 5:e346 Epub 2015 Aug 28 PMID:26314988 PMCID:4558593 DOI:10.1038/bcj.2015.69
60. Rausch Osian S, Leal AD, Allmer C, Maurer MJ, **Nowakowski G**, Inwards DJ, Macon WR, Ehlers SL, Weiner GJ, Habermann TM, Cerhan JR, Thompson CA. Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. Leuk Lymphoma. 2015; 56(2):434-9. PMID:24745936
61. **Nowakowski GS**, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol 2015 Jan 20; 33 (3):251-7 Epub 2014 Aug 18 PMID:25135992 DOI:10.1200/JCO.2014.55.5714
62. Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, Karp JE, Gore SD, Kay NE, Jelinek DF, Witzig TE, **Nowakowski GS**, Kaufmann SH. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood 2015 Jan 22; 125 (4):658-67 Epub 2014 Dec 01 PMID:25452615 PMCID:4304111 DOI:10.1182/blood-2014-04-571786
63. Briski R, Feldman AL, Bailey NG, Lim MS, Ristow K, Habermann TM, Macon WR, Inwards DJ, Colgan JP, **Nowakowski GS**, Kaminski MS, Witzig TE, Ansell SM, Wilcox RA. Survival in patients with limited-stage peripheral t-cell lymphomas. Leuk Lymphoma. 2015 Jun; 56(6):1665-70. PMID:25248884
64. Correia C, Lee SH, Meng XW, Vincelette ND, Knorr KL, Ding H, **Nowakowski GS**, Dai H, Kaufmann SH. Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta. 2015 Jul; 1853(7):1658-71. Epub 2015 Mar 27. PMID:25827952 PMCID:4429517 DOI:10.1016/j.bbamcr.2015.03.012
65. Sammassimo S, Pruneri G, Andreola G, Montoro J, Steffanoni S, **Nowakowski GS**, Gandini S, Negri M, Habermann TM, Raderer M, Li ZM, Zinzani PL, Adam P, Zucca E, Martinelli G. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). Hematol Oncol. 2015 Jul 07. PMID:26152851 DOI:10.1002/hon.2243
66. Witzig TE , Reeder C , Han JJ , LaPlant B , Stenson M , Tun HW , Macon W , Ansell SM , Habermann TM , Inwards DJ , Micallef IN , Johnston PB , Porrata LF , Colgan JP , Markovic S , **Nowakowski GS** , Gupta M . The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood 2015 Jul 16; 126 (3):328-35 Epub 2015 Apr 28 PMID:25921059 PMCID:4504947 DOI:10.1182/blood-2015-02-629543
67. Witzig TE, **Nowakowski GS**, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol. 2015 Aug; 26(8):1667-77. Epub 2015 Feb 23. PMID:25712458 DOI:10.1093/annonc/mdv102
68. Jackson AE, Mian M, Kalpadakis C, Pangalis GA, Stathis A, Porro E, Conconi A, Cortelazzo S, Gaidano G, Lopez Guillermo A, Johnson PW, Martelli M, Martinelli G, Thieblemont C, McPhail ED, Copie-Bergman C, Pileri SA, Jack A, Campo E, Mazzucchelli L, Ristow K, Habermann TM, Cavalli F, **Nowakowski GS**, Zucca E. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Oncologist. 2015 Oct; 20(10):1149-53. Epub 2015 Aug 12. PMID:26268740 PMCID:4591947 DOI:10.1634/theoncologist.2015-0180
69. Damlaj M, Sulai NH, Oliveira JL, Ketterling RP, Hashmi S, Witzig T, **Nowakowski G**, Call TG, Shanafelt TD, Ding W, Hogan WJ, Litzow MR, Patnaik MM. Impact of Alemtuzumab Therapy and Route of Administration in

T-Prolymphocytic Leukemia: A Single-Center Experience. *Clin Lymphoma Myeloma Leuk*. 2015 Nov; 15(11):699-704. Epub 2015 Aug 5 PMID:26422251 DOI:10.1016/j.clml.2015.07.643

70. Thanarajasingam G, Bennani NN, **Nowakowski GS**. Individualized Treatment of Diffuse Large B-cell Lymphoma— The Evolving Role of Molecular-subtype-specific Therapy *Oncology & Hematology Review*. 2015 Nov 2;11:(2):113-4.
71. Church AK, VanDerMeid KR, Baig NA, Baran AM, Witzig TE, **Nowakowski GS**, Zent CS. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages. *Clin Exp Immunol* 2016 Jan; 183 (1):90-101 Epub 2015 Oct 28 PMID:26307241 PMCID:4687519 DOI:10.1111/cei.12697
72. Maurer MJ , Jais JP , Ghesquieres H , Witzig TE , Hong F , Haioun C , Thompson CA , Thieblemont C , Micallef IN , Porrata LF , Ribrag V , **Nowakowski GS** , Casasnovas O , Bologna S , Morschhauser F , Morrison VA , Peterson BA , Macon WR , Copie-Bergman C , Feldman AL , Syrbu SI , Kurtin PJ , Gascoyne RD , Li H , Allmer C , Kahl BS , Ansell SM , Slager SL , Link BK , Salles G , Habermann TM , Tilly H , Cerhan JR . Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. *Am J Hematol* 2016 Feb; 91 (2):179-84 Epub 2015 Nov 26 PMID:26492520 PMCID:4801345 DOI:10.1002/ajh.24223
73. Kenderian SS , Habermann TM , Macon WR , Ristow KM , Ansell SM , Colgan JP , Johnston PB , Inwards DJ , Markovic SN , Micallef IN , Thompson CA , Porrata LF , Martenson JA , Witzig TE , **Nowakowski GS** . Large B-cell transformation in nodular lymphocyte predominant Hodgkin lymphoma: forty-year experience from a single institution. *Blood* 2016 Feb 2 Epub 2016 Feb 02 PMID:26837698 DOI:10.1182/blood-2015-08-665505

Commentaries

1. **Nowakowski GS**. Gang of 3 in aggressive CLL? *Blood*. 2008 Jul 1; 112(1):5-6. PMID:18574035 DOI:10.1182/blood-2008-03-147140
2. **Nowakowski GS**. Evolution: IMiDs to PPMs, revolution in DLBCL? *Blood*. 2015 Aug 6; 126(6):698-700. PMID:26251224 DOI:10.1182/blood-2015-06-649483

Letters

1. Shanafelt TD, Jelinek D, Tschumper R, Schwager S, **Nowakowski G**, DeWald GW, Kay NE. Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia. *J Clin Oncol*. 2006 Jul 1; 24(19):3218-9; author reply 3219-20. PMID:16809747 DOI:10.1200/JCO.2006.06.1077
2. **Nowakowski GS**, Mukhopadhyay D, Wu X, Kay NE. Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells. *Leuk Res*. 2008 Oct; 32(10):1634-6. Epub 2008 Apr 09. PMID:18403014 DOI:10.1016/j.leukres.2008.02.020
3. **Nowakowski GS**, Shanafelt TD, Schwager S, Kay NE. Smudge cells, serum albumin, and prognosis in B-cell chronic lymphocytic leukemia. *J Clin Oncol*. 2009 Aug 1; 27(22):E45.
4. Morice WG, Jevremovic D, Olteanu H, Roden A, **Nowakowski G**, Kroft S, Hanson CA, Kurtin PJ. Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets. *Leukemia*. 2010 Apr; 24(4):881-4. Epub 2010 Jan 28. PMID:20111066 DOI:10.1038/leu.2009.304
5. **Nowakowski GS**, Maurer MJ, Witzig TE, Cerhan JR. Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma. *J Clin Oncol*. 2010 Aug 20; 28(24):E427-8.
6. **Nowakowski GS**, Witzig TE, Maurer MJ, Cerhan JR. Reply to J.R. Carver et al. *J Clin Oncol*. 2010 Aug 30. [Epub ahead of print] PMID:20805452 DOI:10.1200/JCO.2010.30.2752
7. **Nowakowski GS**, Witzig TE, Maurer MJ, Cerhan JR. Rituximab and statins. *J Clin Oncol*. 2010 Oct;

28(30):E612.

8. Wu X, Smoley SA, Peterson MA, Walters DK, Arendt BK, **Nowakowski GS**, Van Dyke DL, Kay NE, Jelinek DF. Biological evaluation of CpG stimulation of normal human B-cells: implications for B-cell biology and cytogenetic analysis of CLL B-cells. *Br J Haematol*. 2011 May; 153(3):402-5. Epub 2011 Feb 17. PMID:21323871 DOI:10.1111/j.1365-2141.2010.08514.x
9. Asmann YW, Maurer MJ, Wang C, Sarangi V, Ansell SM, Feldman AL, **Nowakowski GS**, Manske M, Price-Troska T, Yang ZZ, Slager SL, Habermann TM, Cerhan JR, Novak AJ. Genetic diversity of newly diagnosed follicular lymphoma. *Blood Cancer J*. 2014; 4:e256. Epub 2014 Oct 31. PMID:25360902 DOI:10.1038/bcj.2014.80
10. Tsang M , Shanafelt TD , Call TG , Ding W , Chanan-Khan A , Leis JF , **Nowakowski GS** , Bowen D , Conte M , Schwager SM , Slager SL , Kay NE , Hanson CA , Parikh SA . The efficacy of ibrutinib in the treatment of Richter syndrome. *Blood* 2015 Mar 5; 125 (10):1676-8 PMID:25745187 DOI:10.1182/blood-2014-12-610782
11. Weinstock DM, Dalla-Favera R, Gascoyne RD, Leonard JP, Levy R, Lossos IS, Melnick AM, **Nowakowski GS**, Press OW, Savage KJ, Shipp MA, Staudt LM. A roadmap for discovery and translation in lymphoma. *Blood*. 2015 Mar 26; 125(13):2175-7. PMID:25814490 DOI:10.1182/blood-2015-01-623777
12. **Nowakowski GS**, Macon WR, Gascoyne RD, Witzig TE. Reply to M. Gleeson et al. *J Clin Oncol* 2015 Oct 1; 33 (28):3216-7 Epub 2015 Aug 10 PMID:26261258 DOI:10.1200/JCO.2015.61.8280

Abstracts

1. **Nowakowski GS**, Morice WG, Tefferi A, Phyliky RE. Acquired pure red cell aplasia associated with clonal T-cell receptor (TCR) gene rearrangements with and without pathologic features of T-cell large granular lymphocytic leukemia (T-LGLL). *Blood*. 2004 Nov 16; 104(11 Part 1):771A.
2. **Nowakowski GS**, Dewald GW, Paternoster SF, Fink SR, Smoley SA, Remstein ED, Hoyer JD, Phyliky RL, Call TG, Shanafelt TD, Zent CS. Interphase fluorescence in situ hybridization (FISH) with an IgH probe is important in the management of patients with a clinical diagnosis of chronic lymphocytic leukemia (CLL). *Blood*. 2004 Nov 16; 104(11 Part 1):530A-1A.
3. Shanafelt TD, Geyer S, Bone N, Schwager S, Lee YK, **Nowakowski G**, Call TG, Zent CS, Kay NE. Evaluation of the prognostic implications of pro- and anti-angiogenic cytokines in 311 patients with untreated chronic lymphocytic leukemia (Abstract 712). *Blood*. 2005 Nov; 106(11):211a.
4. Dingli D, **Nowakowski GS**, Dispenzieri A, Lacy MQ, Hayman SR, Rajkumar VS, Greipp PR, Litzow MR, Gastineau DA, Witzig TE, Gertz MA. Flow cytometric detection of circulating myeloma cells pretransplant in patients with multiple myeloma: a simple risk stratification system (Abstract 1164). *Blood*. 2005 Nov; 106(11):340a.
5. **Nowakowski GS**, Lee YK, Bone ND, Morice WG, Barnidge D, Jelinek DF, Tschumper R, Shanafelt TD, Zent CS, Rassenti LZ, Kipps TJ, Kay NE. Proteomic analysis of chronic lymphocytic leukemia cells identifies vimentin as a novel prognostic factor for aggressive disease (Abstract 707). *Blood*. 2005 Nov; 106(11):209a.
6. **Nowakowski GS**, Witzig TE, Bone ND, Lee YK, Shanafelt TD, Kay NE. Targeting V α -4 reduces cell adhesion mediated drug resistance in chronic lymphocytic leukemia: rationale for anti V α -4 therapy (Abstract 1182). *Blood*. 2005 Nov; 106(11):345a.
7. **Nowakowski GS**, Li CY, Dingli D, Kumar S, Gertz MA, Lacy MQ, Lust JA, Dispenzieri A, Greipp PR, Zeldenrust S, Buadi F, Hayman S, Kyle RA, Rajkumar VS. Increased cytotoxic T-cell infiltrates in the bone marrow is an independent adverse prognostic factor in patients with newly diagnosed multiple myeloma. *Blood*. 2007 Nov; 110(11):446A-7A.
8. **Nowakowski GS**, Wu XS, Abrahamzon JL, Tschumper R, Kay NE, Jelinek DF. ABCG2 is expressed in a small population of circulating CLL B-cells characterized by expression of self-renewal and early B-cell development

genes and resistance to therapy. *Blood*. 2008 Nov; 112(11):1082.

9. Wu XS, **Nowakowski GS**, Smoley SA, Arendt BA, Peterson MA, van Dyke D, Kay NE, Jelinek DF. Cytogenetic analysis of normal human B cells following CpG stimulation: implications for interpretation of CpG induced CLL metaphase analysis. *Blood*. 2008 Nov; 112(11):1071.
10. **Nowakowski GS**, Maurer MJ, Habermann TM, Ansell SM, Macon WR, Ristow KM, Allmer C, Stager SL, Witzig TE, Cerhan JR. Statin use and prognosis in patients with follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL). *Blood*. 2008 Nov; 112(11):219.
11. **Nowakowski GS**, LaPlant B, Habermann T, Inwards DJ, Johnston PL, Zent CS, Reeder CB, Witzig TE. A phase I/II trial of lenalidomide and RCHOP (R2CHOP) in patients with newly diagnosed diffuse large B -cell (DLBCL) and follicular grade 3 lymphoma. *Blood*. 2009 Nov 20; 114(22):666.
12. Wu XS, Tschumper RC, Gutierrez A, Mihalcik SA, **Nowakowski GS**, Capello D, Jelinek DF. Somatic hyperrepair: a novel tumor suppression mechanism for germinal center B cells. *Blood*. 2009 Nov 20; 114(22):43.
13. Mraz M, Zent C, Church A, Jelinek D, Wu X, Pospisilova S, Ansell S, Novak A, Witzig T, **Nowakowski G**. Targeting integrin/CD49D/VLA4 with natalizumab can inhibit adhesion of malignant B cells and sensitize them to chemoimmunotherapy. *Haematologica*. 2010 Jun; 95(Suppl 2):0437.
14. **Nowakowski GS**, Ristow K, Kurtin P, Allen MS, Micallef IN, Colgan J, Inwards DJ, McPhail E, Markovic S, Ansell SM, Porrata L, Johnston PB, Thompson CA, Witzig TE, Habermann TM. Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience. *Blood*. 2010 Nov; 116(21):1696.
15. Witzig TE, Hui T, Micallef IN, Ansell SM, Link B, Inwards DJ, Porrata L, Johnston PB, Colgan J, Markovic S, **Nowakowski GS**, Thompson CA, Allmer C, Maurer MJ, Weiner G, Hohl RJ, Kurtin P, Ding HS, David LA, Schneider PA, Peterson KL, Habermann TM, Kaufmann SH. A phase II study of the farnesyltransferase inhibitor tipifarnib demon strates anti tumor activity in patients with relapsed and refractory lymphomas. *Blood*. 2010 Nov 19; 116(21):130-1.
16. Baig NA, Church AK, **Nowakowski GS**, Taylor RP, Lindorfer MA, Zent CS. Complement activation and cytotoxicity in CLL cells treated with alemtuzumab and ofatumumab evidence for multiple mechanisms of resistance to complement dependent cytotoxicity. *Blood*. 2010 Nov 19; 116(21):1472.
17. Maurer MJ, Cerhan J, Katzmann JA, Link B, Micallef IN, Colgan J, Habermann TM, Inwards DJ, Markovic S, Ansell SM, Porrata L, Johnston PB, **Nowakowski GS**, Thompson CA, Gupta M, Syrbu SI, Kurtin P, Macon W, Witzig TE. Elevation of serum free light chains are common in lymphoma and associated with poor event free and overall survival. *Blood*. 2010 Nov 19; 116(21):1683.
18. Cerhan JR, Habermann TM, Maurer MJ, Wooldridge JE, Ansell SM, **Nowakowski GS**, Micallef IN, Thompson CA, Wang AH, Macon WR, Syrbu SI, Slager SL, Witzig TE, Link B. Genetic polymorphisms in genes involved in R CHOP metabolism and event free and overall survival in diffuse large B cell lymphoma. *Blood*. 2010 Nov 19; 116(21):439.
19. Mraz M, Zent CS, Church AK, Baig NA, Jelinek DF, Wu XS, Pospisilova S, Ansell SM, Novak AJ, Witzig TE, **Nowakowski GS**. Interactions with the microenvironment protect lymphoma B cells from rituximab induced apoptosis and could represent a therapeutic target. *Blood*. 2010 Nov 19; 116(21):1284.
20. Kumar S, Porrata LF, Ansell SM, Colgan JP, LaPlant B, Gertz MA, Inwards DJ, Johnston PB, Haberman T, Micallef IN, **Nowakowski GS**, Witzig TE. Phase 1 trial of sorafenib and everolimus in patients with lymphoma or multiple myeloma. *Blood*. 2010 Nov 19; 116(21):1155-6.
21. Ansell SM, Tang H, **Nowakowski GS**, Nikcevich D, Nelson GD, Erlichman C, Witzig TE. Phase II clinical trial of denileukin diftitox in combination with rituximab in previously untreated follicular B cell non Hodgkin's lymphoma.

Blood. 2010 Nov 19; 116(21):1178-9.

22. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef I, Johnston PB, Colgan J, **Nowakowski GS**, Witzig TE, Ansell SM, Markovic S, Porrata L. The absolute monocyte and lymphocyte counts at diagnosis predict survival and identify high risk patients in diffuse large B cell lymphoma. *Blood*. 2010 Nov 19; 116(21):1273.
23. Dao LN, Law ME, **Nowakowski CS**, Macon WR. CD23 and TRAF1 expression and lack of BCL2/IGH fusion help discriminate primary mediastinal large B-cell lymphoma from mediastinal involvement by systemic DLBCL. *Mod Pathol*. 2011 Feb; 24(Suppl 1):293A.
24. Dao LN, Law ME, **Nowakowski GS**, Macon WR. CD23 and TRAF1 expression and lack of BCL2/IGH fusion help discriminate primary mediastinal large B-cell lymphoma from mediastinal involvement by systemic DLBCL. *Lab Invest*. 2011 Feb; 91(Suppl 1):293A.
25. **Nowakowski G**, Reeder CB, Laplant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Johnston PB, Micallef IN, Porrata LF, Klebig RR, Nelson GD, Ansell SM, Witzig TE. Combination of lenalidomide with r-chop (r2chop) is safe and effective as initial therapy for aggressive b-cell lymphomas - a phase I/II study. *Ann Oncol*. 2011 Jun; 22(Suppl 4):119.
26. Thompson CA, Luo HX, Maurer MJ, Allmer C, Habermann TM, **Nowakowski GS**, Inwards DJ, Johnston PB, Porrata LF, Witzig TE, Roger V, Cerhan JR. Cardiac outcomes in a prospective cohort of adult non-Hodgkin lymphoma survivors. *Blood*. 2011 Nov 18; 118(21):1141.
27. Porrata LF, Ristow KM, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, **Nowakowski GS**, Thompson CA, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin's lymphoma. *Blood*. 2011 Nov 18; 118(21):1555.
28. Porrata LF, Ristow KM, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, **Nowakowski GS**, Thompson CA, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis is independent of the cell of origin in predicting survival in diffuse large B-cell lymphoma. *Blood*. 2011 Nov 18; 118(21):1560-1.
29. Kumar S, Mikhael JR, LaPlant BR, Colgan JP, Inwards DJ, Johnston PB, Laumann K, Micallef IN, **Nowakowski GS**, Ansell SM, Curtis K, Dispenzieri A, Lacy MQ, Leis JF, Northfelt D, Reeder CB, Slack JL, Witzig TE. Phase I trial of a novel combination of an HDAC inhibitor (LBH589) and an mTOR inhibitor (RAD001) in lymphoid and plasma cell malignancies. *Blood*. 2011 Nov 18; 118(21):1152-3.
30. Sammassimo S, Pruneri G, Adam P, Pileri S, Rafaniello P, Steffanoni S, Gandini S, Negri M, Habermann TM, Li ZM, Zinzani PL, Raderer M, Armitage JO, Weisenburger DD, Bairey O, Cabrera M, Zucca E, Puccini B, Gutierrez-Garcia G, Kalinka-Warzocha E, Carpaneto A, Besson C, Porro E, Cavalli F, **Nowakowski GS**, Martinelli G. Potential pathogenetic role of achromobacter (*alcaligenes*) xylosoxidans in primary extranodal marginal zone lymphoma of the lung (BALT-lymphoma): update of the results of a retrospective analysis on behalf of IELSG. *Blood*. 2011 Nov 18; 118(21):402-3.
31. Jones JM, Habermann TM, Ristow KM, Kurtin P, McPhail E, Thompson CA, Colgan JP, Porrata LF, Markovic SN, Witzig TE, Martenson JA Jr, **Nowakowski GS**. Primary parotid MALT, lymphoma: clinical characteristics and treatment a single institution experience. *Blood*. 2011 Nov 18; 118(21):686-7.
32. Burnette BL, Wiseman G, Habermann TM, Ansell SM, Porrata LF, Inwards DJ, Johnston PB, Micallef I, Macon WR, Witzig TE, **Nowakowski GS**. Prior rituximab exposure does not appear to affect time to treatment failure after radioimmunotherapy. *Blood*. 2011 Nov 18; 118(21):712-3.
33. Baig NA, Taylor RP, Lindorfer MA, Church AK, LaPlant BR, Pavey ES, Shanafelt TD, Call TG, Kay N, **Nowakowski GS**, Zent CS. Resistance to complement dependent cytotoxicity in CLL cells from patients treated with ofatumumab. *Blood*. 2011 Nov 18; 118(21):1222.

34. Burnette BL, Wiseman G, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Ristow KM, Witzig TE, **Nowakowski GS**. Risk of transformation of follicular lymphoma to high grade lymphoma after radioimmunotherapy: a prospective observational single institutional experience. *Blood*. 2011 Nov 18; 118(21):683.
35. Wilcox RA, Ristow KM, Habermann TM, Inwards DJ, Micallef IM, Johnston PB, Colgan JP, **Nowakowski GS**, Ansell SM, Witzig TE, Markovic SN, Porrata LF. The absolute monocyte count predicts overall survival in patients newly diagnosed with follicular lymphoma. *Blood*. 2011 Nov 18; 118(21):40-1.
36. Klebig RR, Ansell SM, Colgan JP, Gastineau DA, Habermann TM, Johnston PB, Markovic SN, Micallef IN, **Nowakowski GS**, Porrata LF, Ristow KM, Thompson CA, Towns JN, Witzig TE, Inwards DJ. Utility of stem cell collection in anticipation of future need for autologous stem cell transplant in follicular lymphoma patients. *Blood*. 2011 Nov 18; 118(21):840.
37. West DS, Dogan A, Ketterling RP, Law ME, McPhail ED, Viswanatha DS, Kurtin PJ, Dao LN, Ritzer RD, **Nowakowski GS**, Feldman AL. Clonally related follicular lymphoma and Langerhans cell neoplasm: a study of 2 cases. *Mod Pathol*. 2012 Feb; 25:380A.
38. West DS, Dogan A, Ketterling RP, Law ME, McPhail ED, Viswanatha DS, Kurtin PJ, Dao LN, Ritzer RD, **Nowakowski GS**, Feldman AL. Clonally related follicular lymphoma and langerhans cell neoplasm: a study of 2 cases. *Lab Invest*. 2012 Feb; 92:380A.
39. Sirop SJ, Habermann TM, Macon WR, Ristow KM, Ansell SM, Colgan JP, Johnston PB, Inwards DJ, Markovic SN, Micallef IN, Thompson C, Porrata LF, Martenson JA, Cerhan JR, Witzig TE, **Nowakowski GS**. Diffuse large b-cell transformation in nodular lymphocyte predominant hodgkin lymphoma: incidence, risk factors and outcomes after a forty-year experience from a single institution. *Blood*. 2012 Nov 16; 120(21).
40. Cerhan JR, **Nowakowski GS**, Maurer MJ, Charbonneau B, Ghesquieres H, Novak AJ, Asmann YW, Dogan A, Markovic SN, Thompson CA, Ansell SM, Weiner GJ, Link BK, Habermann TM, Slager SL. Germline genetic variation and risk of follicular lymphoma transformation in the modern treatment era. *Blood*. 2012 Nov 16; 120(21).
41. Reeder C, Ansell SM, Gano K, Dueck AC, Conley C, **Nowakowski GS**, Curtis K, Camoriano J, Leis J, Slack JL, Valdez R, Tiedemann RE, Stewart K, Witzig TE. LR-CD: efficacy of combination therapy with lenalidomide for untreated indolent b-cell nhl. *Blood*. 2012 Nov 16; 120(21).
42. Jacobus LS, Lunde J, Maurer MJ, Dogan A, Syrbu SI, Allmer C, Novak AJ, Cerhan JR, **Nowakowski GS**, Slager SL, Witzig TE, Thompson CA, Weiner GJ, Habermann TM, Ansell SM, Link BK. Non-follicular low grade b-cell lymphomas: patterns of presentation and management with comparative prognostic utility of ipi and flipi. *Blood*. 2012 Nov 16; 120(21).
43. Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, **Nowakowski GS**, Thompson CA, Markovic SN. Peripheral blood absolute lymphocyte/monocyte ratio at diagnosis is independent of the interim positron-emission tomography in predicting progression-free survival and time to progression in classical Hodgkin lymphoma (hl). *Blood*. 2012 Nov 16; 120(21).
44. Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, **Nowakowski GS**, Thompson CA, Markovic SN. Peripheral blood absolute lymphocyte/monocyte ratio recovery during abvd treatment cycles predicts clinical outcomes in classical hodgkin lymphoma (hl). *Blood*. 2012 Nov 16; 120(21).
45. Link BK, Maurer MJ, **Nowakowski GS**, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Weiner GJ, Habermann TM, Cerhan JR. Rates and outcomes of follicular lymphoma transformation in the rituximab era: a report from the university of iowa/mayo clinic spore molecular epidemiology resource. *Blood*. 2012 Nov 16; 120(21).

46. Jones JM, Dogan A, Ziesmer SC, **Nowakowski GS**, Ristow KM, Yang ZZ, Cerhan JR, Ansell SM. The presence of intratumoral cd14 positive cells is associated with transformation of follicular lymphoma to diffuse large b cell lymphoma. *Blood*. 2012 Nov 16; 120(21).
47. Tagliente DJ, King RL, Neff J, **Nowakowski GS**, Howard MT, Morice WG. Chronic lymphoproliferative disorder of natural killer cells (clpd-nk): a singular entity resembling t-cell large granular lymphocytic leukemia (t-lgl) or a heterogeneous group of conditions? *Mod Pathol*. 2013 Feb; 26:363A.
48. Tagliente DJ, King RL, Neff J, **Nowakowski GS**, Howard MT, Morice WG. Chronic lymphoproliferative disorder of natural killer cells (clpd-nk): a singular entity resembling t-cell large granular lymphocytic leukemia (t-lgl) or a heterogeneous group of conditions? *Lab Invest*. 2013 Feb; 93:363A.
49. Sirop SJ, Habermann TM, Macon WR, Ristow KM, Ansell SM, Colgan JP, Johnston PB, Markovic SN, Micallef IN, Thompson CA, Porrata LF, Martenson JA, Witzig TE, **Nowakowski GS**, Inwards DJ. Salvage autologous stem cell transplantation for nodular lymphocyte predominant hodgkin lymphoma: a single institution experience. *Biol Blood Marrow Transplant*. 2013 Feb; 19(2):S189-90.
50. Ernst B, Dueck AC, Toro A, Johnston PB, Haberman T, Leis JF, Mikhael JR, **Nowakowski GS**, Colgan JP, Porrata LF, Slack JL, Ansell SM, Witzig TE, Reeder CB. A novel combination of the mtorc1 inhibitor everolimus and the immunomodulatory (imid) drug lenalidomide produces durable responses in patients with heavily pretreated relapsed lymphoma. *Blood*. 2014 Dec 6; 124(21):3100.
51. Maurer MJ, Ghesquieres H, Ansell SM, Thompson CA, **Nowakowski GS**, Inwards DJ, Allmer C, Nicolas-Virelizier E, Sebban C, Biron P, Chassagne-Clement C, Gargi T, Macon WR, Feldman AL, Syrbu SI, Slager SL, Witzig TE, Habermann TM, Link BK, Cerhan JR. Event-free survival at 12 months (efs12) from diagnosis is a robust endpoint for disease-related survival in patients with follicular lymphoma in the immunochemotherapy era. *Blood*. 2014 Dec 6; 124(21):1664.
52. Jackson AE, Mian M, Kalpadakis CH, Pangalis GA, Stathis A, Porro E, McPhail ED, Habermann TM, Ristow KM, Cavalli F, **Nowakowski GS**, Zucca E. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (malt) of the salivary gland is associated with improved prognosis when arising in a background of Sjogren's disease and may not benefit from local therapy. *Blood*. 2014 Dec 6; 124(21).
53. Asmann Y, Maurer MJ, Sarangi V, Ansell SM, Feldman AL, **Nowakowski GS**, Manske MK, Troska TP, Yang ZZ, Slager SL, Habermann TM, Cerhan JR, Novak AJ. Genomic diversity of newly diagnosed follicular lymphoma: a pilot investigation. *Blood*. 2014 Dec 6; 124(21):1691.
54. Damlaj M, Hashmi S, Call T, Witzig TE, **Nowakowski GS**, Shanafelt T, Ding W, Oliveira J, Ketterling R, Litzow MR, Hogan W, Patnaik M. Feasibility of hematopoietic stem cell transplantation for t-prolymphocytic leukemia. experience of a large referral center. *Biol Blood Marrow Transplant*. 2015 Feb; 21(2):S185.
55. **Nowakowski GS**, LaPlant B, Macon WR, Gertz MA, Habermann TM, Inwards DJ, Micallef INM, Wender DB, Leonard J, Witzig TE. Bendamustine and rituximab and lenalidomide (brr) in the treatment of relapsed and refractory low grade non-hodgkin lymphoma (nhl): Final results of phase 1 study ncctg n1088/alliance. *J Clin Oncol*. 2015 May 20; 33(15).
56. Johnston PB, LaPlant B, **Nowakowski GS**, Micallef INM, Ansell SM, Habermann TM, Colgan J, Witzig TE. Combination of everolimus with r-chop (ever r-chop) as an initial therapy for diffuse large b-cell lymphoma (dlbcl): a phase i and feasibility study (ncctg n1085 [alliance]). *J Clin Oncol*. 2015 May 20; 33(15).
57. Ferzoco RM, Cerhan JR, Maurer MJ, Allmer C, Yost KJ, Habermann TM, Ansell SM, Inwards DJ, Witzig TE, Porrata LF, **Nowakowski GS**, Macon WR, Towns JN, Farooq U, Link BK, Thompson CA. Exercise patterns and quality of life among survivors of aggressive lymphoma. *J Clin Oncol*. 2015 May 20; 33(15).
58. **Nowakowski GS**, Chiappella A, Witzig TE, Spina M, Zhang L, Flament J, Repici J, Vitolo U. Randomized, phase iii trial of the efficacy and safety of lenalidomide plus r-chop vs r-chop in patients with untreated abc-type diffuse large b-cell lymphoma. *J Clin Oncol*. 2015 May 20; 33(15).

59. Rosenthal A , Dueck AC , Ansell SM , Gano K , Conley C , **Nowakowski GS** , Curtis K , Camoriano J , Leis JF , Slack J , Valdez R , Mikhael JR , Stewart AK , Inwards D , Dingli D , Kumar S , Noel P , Gertz M , Porrata L , Russell S , Colgan J , Fonseca R , Habermann TM , Kapoor P , Buadi F , Leung N , Tiedemann R , Witzig TE , Reeder C . A phase 2 study of lenalidomide, rituximab, cyclophosphamide and dexamethasone (lr-cd) for untreated low grade non-Hodgkin lymphoma requiring therapy *Clinical Lymphoma Myeloma & Leukemia* 2015 Jun; 15:S225-6
60. Damlaj M, Alkhateeb H, Tibes R, **Nowakowski G**, McAllister T, Pardananani A, Viswanatha D, Lazaridis K, Feldman A, Wieben E, Egan JB, Bryce A, Fernandez-Zapico ME, Patnaik M. Next generation sequencing of myeloid malignancies identified a spectrum of novel mutations in epigenetic regulators - center for individualized medicine clinic experience. *Haematologica*. 2015 Jun; 100:357-8.
61. Zent C , Church A , VanDerMeid K , Baig N , Baran A , Witzig T , **Nowakowski G** . Anti-cd20 monoclonal antibody dependent phagocytosis of chronic lymphocytic leukemia cells by autologous macrophages *Leukemia & Lymphoma* 2015 Sep 1; 56:166
62. Johnston PB , Laplant BR , McPhail ED , Habermann TM , Inwards DJ , Micallef IN , Colgan JP , **Nowakowski GS** , Ansell S , Witzig TE . Everolimus plus rchop-21 is safe and highly effective for new untreated diffuse large b-cell lymphoma (dlbcl): results of the phase i trial nctg1085 (alliance) *Blood* 2015 Dec 3; 126 (23):813
63. Maurer MJ , Thompson CA , Farooq U , Lin T , **Nowakowski GS** , Lin Y , Micallef I , Novak A , Macon W , Syrbu S , Cerhan J , Witzig TE , Habermann TM , Ansell S , Link BK . Incidence and outcomes of treatment refractory diffuse large b-cell lymphoma in the immunochemotherapy era *Blood* 2015 Dec 3; 126 (23):3992
64. Porrata L , Ristow K , McPhail ED , Macon W , Maurer MJ , **Nowakowski GS** , Ansell S , Witzig TE , Markovic S , Habermann TM . Lymphocyte-to-monocyte ratio at diagnosis and survival in de novo double/triple hit diffuse large b-cell lymphoma *Blood* 2015 Dec 3; 126 (23):3885
65. Thanarajasingam G , Maurer MJ , Farooq U , Johnston PB , Thompson C , Ansell S , Porrata L , Macon W , Syrbu S , Cerhan J , Habermann TM , Witzig TE , Link BK , **Nowakowski GS** . Natural history of central nervous system relapse in diffuse large b cell lymphoma in the immunochemotherapy era *Blood* 2015 Dec 3; 126 (23):1456
66. Lin T , Alkhateeb HB , Al-Kali A , Elliott MA , Gangat N , Hogan WJ , **Nowakowski GS** , Thompson CA , Witzig TE , Ansell SM , Litzow MR , Patnaik MM . Prognostic correlates and outcomes of relapsed t-cell acute lymphoblastic leukemia/lymphoma: an analysis of 41 consecutive patients *Blood* 2015 Dec 3; 126 (23):3730
67. Asmann Y , Sarangi V , Wang C , Maurer MJ , Ansell S , Feldman AL , **Nowakowski GS** , Habermann TM , Novak AJ , Slager SL , Link BK , Cerhan J . Study of the subclonal mutations in primary diffuse large b-cell lymphoma *Blood* 2015 Dec 3; 126 (23):131
68. Alkhateeb HB , Lin T , Damlaj M , Al-Kali A , Gangat N , Hogan WJ , Elliott M , **Nowakowski GS** , Thompson C , Witzig TE , Ansell SM , Litzow MR , Patnaik MM . Survival trends in adult t-acute lymphoblastic leukemia / lymphoma (all), a comparative analysis of 92 patients by year of diagnosis *Blood* 2015 Dec 3; 126 (23):2490
69. Alkhateeb HB , Damlaj M , Lin T , Hefazi M , Al-Kali A , Gangat N , Hogan WJ , Elliott M , **Nowakowski GS** , Thompson C , Witzig TE , Ansell SM , Litzow MR , Patnaik MM . The adverse impact of age and central nervous system involvement on survival in adult t-all, an analysis of 92 consecutive patients *Blood* 2015 Dec 3; 126 (23):4993
70. Farooq U , Maurer MJ , Ansell SM , Lin T , **Nowakowski GS** , Porrata L , Inwards DJ , Macon W , Sergei S , Cerhan J , Witzig TE , Link BK , Habermann TM , Thompson CA . Treatment patterns and outcomes of dlbcl after failure of front-line immunochemotherapy *Blood* 2015 Dec 3; 126 (23):2683
71. King R , Scott DW , Gascoyne RD , Fitzgibbons MA , **Nowakowski GS** , Witzig TE , Macon WR . Pathology

review for ecog 1412: a comparison of nanostring gene expression profiling and immunohistochemistry for cell-of-origin testing in de-novo diffuse large b-cell lymphoma Laboratory Investigation 2016 Feb; 96:356A

72. King R , Scott DW , Gascoyne RD , Fitzgibbons MA , **Nowakowski GS** , Witzig TE , Macon WR . Pathology review for ecog 1412: a comparison of nanostring gene expression profiling and immunohistochemistry for cell-of-origin testing in de-novo diffuse large b-cell lymphoma Modern Pathology 2016 Feb; 29:356A

(b) (6)